Implications of Clozapine Monitoring During the COVID-19 Pandemic

What is it about?

Highlights: A consensus statement released after the COVID-19 pandemic was declared in 2020 recommended that laboratory monitoring may be reduced to every three months for patients receiving continuous clozapine treatment for at least one year to decrease the risk of discontinuation. Less frequent absolute neutrophil count (ANC) monitoring due to the COVID-19 pandemic did not lead to increased incidence of clozapine discontinuation due to severe neutropenia. Risk Evaluation and Mitigation Strategies (REMS) requirements may be interested in this data which demonstrates the feasibility and safety of extended interval laboratory monitoring for patients receiving clozapine treatment for greater than one year.

Featured Image